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OBJECTIVE: Lymph node metastasis (LNM) rarely occurs in hepatocellular carcinoma (HCC). Few 
studies have reported the potential risk factors of LNM and the influence of LNM on the progression and
prognosis of HCC. The purposes of this study were to explore the clinicopathological characteristics of
operable HCC with LNM and to demonstrate the effects of LNM on HCC prognosis.
METHODS: A retrospective review of 2,034 HCC patients undergoing surgery from 1982 to 2005 was
performed. The influence of LNM was assessed by clinicopathological factors, tumour recurrence, and
overall survival. A total of 66 randomly selected patients matched for clinicopathological variables were
used to analyse the difference in survival. 
RESULTS: A total of 25 patients (1.23%) were reported to have LNM. Higher preoperative carcinoembry-
onic antigen levels (> 10 ng/mL) were significantly associated with a higher incidence of LNM than were
low preoperative carcinoembryonic antigen levels (≤ 10 ng/mL) (15.38% vs. 3.79%, p = 0.042). Furthermore,
HCC with LNM (N1 disease) was larger in size (mean, 9.44 vs. 5.85 cm, p = 0.016) and significantly associ-
ated with vascular invasion, worse histological grade, and nonencapsulation (p = 0.002, < 0.001, and
< 0.001, respectively). Finally, patients with HCC accompanied by LNM had shorter mean disease-free
survival and overall survival (p = 0.001 and < 0.001, respectively). 
CONCLUSION: This study identified the worst prognosis of HCC in a population with LNM. HCC with
LNM tends to be the infiltrating type with larger tumour size (> 5 cm), presence of microvascular inva-
sion, and worse histological grade. Liver resection with lymphadenectomy is possibly beneficial for
patients with HCC accompanied by LNM. [Asian J Surg 2011;34(2):53–62]
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Introduction
Hepatocellular carcinoma (HCC) is the most common
primary malignancy of the liver with an estimated annual
death incidence of 598,000 worldwide. In Taiwan, it is the
second most common cause of cancer death and causes
more than 7,500 deaths each year.1 Surgical resection
remains the most effective therapy in selected patients,
but approximately 75% of patients with HCC have advanced
unresectable diseases upon presentation. In addition,
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metastasis to peri-hepatic lymph nodes noted during 
surgery is historically deemed to be a poor prognostic 
factor.2–5 Compared with other malignancies such as lung
cancer, oesophageal cancer, renal cancer, gastric cancer,
and intra-hepatic cholangiocarcinoma, the incidence of
lymph node metastasis (LNM) in HCC is very low, and
data regarding HCC with LNM are quite limited.6–12
Previous reports have shown that the survival of patients
with HCC accompanied by LNM matched the survival of
those with major vascular invasion (T3).2 Therefore, they
proposed simplification of the fifth edition of AJCC
(American Joint Committee on Cancer) Cancer Staging
Manual by regrouping T3N0M0 tumours into stage IIIA
and T1–4N1M0 tumours into stage IIIB. The latest sev-
enth edition of AJCC Cancer Staging Manual has further
classified N1 diseases into stage IVa because the survival
of N1 disease is comparable with that of M1 disease.13
These studies and the TNM staging system suggested
that HCC with LNM is associated with a dismal progno-
sis. However, very few studies have reported the potential
risk factors of LNM.
Recent studies revealed that higher carcinoembryonic
antigen (CEA) expression can be found in patients with
LNM and recurrent tumours of fibrolamellar carcinoma,
a rare variant of HCC.14 In addition, a high serum CEA
level is also linked to a more advanced stage of pancreatic
cancer15 and is an appropriate marker for early detection of
recurrent colorectal liver metastasis.16 Thus, CEA expres-
sion might be associated with a more aggressive biological
behaviour of HCC, such as LNM, distant metastasis, and
recurrences. Nevertheless, there are no studies demon-
strating the possible relationships between the CEA level
and clinical characteristics of HCC, especially LNM.
Therefore, the aims of this study were to explore the
clinicopathological characteristics of operable HCC with
LNM and to demonstrate the effects of LNM on HCC
prognosis in a large cohort of HCC patients. In addition,
the predictive value of CEA levels on LNM was inves-
tigated, which may detect patients at risk of LNM and
allow for the implementation of appropriate treatment.
Patients and methods
Patients
From 1982 to 2005, records of patients with histologically
proven primary HCC from the Cancer Registry of the
Cancer Center, Chang Gung Memorial Hospital, Linkou,
Taiwan, were retrospectively reviewed. Only patients who
underwent either curative hepatectomy or exploratory
laparotomy for tissue diagnosis (operable HCC confirmed
by imaging) by the same surgical team were included in
our study. A total of 2,034 patients were evaluated, and
their clinicopathological data were retrieved from the
prospectively collected database. The following variables
were included in the analyses: age, gender, cigarette smoking,
alcohol consumption, hepatitis B virus (HBV) infection,
anti-hepatitis C virus antibody (anti-HCV) level, albumin
level, bilirubin level, preoperative alpha-foetoprotein level,
preoperative CEA level, tumour-LNM status, tumour
encapsulation, histological grade, tumour recurrence, and
mortality. The study endpoint was 30 June 2010, and
tumour staging was based on the 6th edition of AJCC
TNM staging system for HCC.17
This study was conducted in a retrospective case-
control manner. HCC patients with pathologically proven
LNM were compared with those without LNM. Absence
of LNM was confirmed by the following three criteria: (1)
negative reports of preoperative computed tomography
scans, interpreted by experienced radiologists; (2) no
intra-operative detectable enlarged lymph nodes, proven
by experienced hepatobiliary surgeons; and (3) negative
postoperative pathological report of LNM in the resected
specimen, examined by pathologists who were experts in
hepatology.
Surgical procedures
The indications for surgery included a lack of cancerous
thrombi in the main trunk of the portal vein, no distant
metastasis to other organs, and a technically operable
main tumour in the preoperative evaluation.18−20 Suspected
LNM restricted to the hepatoduodenal ligament, detected
by a preoperative image study, was defined as HCC opera-
ble by experienced surgeons, and hepatectomy combined
with lymph node dissection was performed.
If the tumour and LNM invaded or encased major ves-
sels or if cancerous carcinomatosis was identified during
surgery, the tumour was deemed unresectable and only a
wedge biopsy of the liver mass was performed for a post-
operative histological diagnosis. The hepatic hilum and
hepatoduodenal ligament were carefully examined and
palpated to detect any enlarged lymph nodes by the chief
surgeons. Any enlarged lymph node was considered suspi-
cious for metastasis, and lymphadenectomy was performed
if the main tumour was resectable. Lymphadenectomy
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meant complete excision of soft tissue and lymph nodes
(skeletonisation) at the hepatic hilum, hepatoduodenal
ligament, and common hepatic artery stations. In addi-
tion, any other enlarged lymph nodes in the vicinity of the
primary tumour were removed for pathologic diagnosis.
On the other hand, only an incisional biopsy of the enlarged
lymph node was performed if the primary tumour was
unresectable. All resected or biopsied specimens were
examined by independent experienced pathologists.
Statistical analysis
The statistical analysis was performed with SPSS 13.0 for
Windows (SPSS Inc., Chicago, IL, USA). Fisher’s exact test
and Pearson’s χ2 test were used to analyse categorical
data. Student’s t test was used to analyse quantitative vari-
ables. Compared with 22 patients with LNM, a total of 
66 randomised patients matched for clinicopathological
variables were selected to conduct the survival analysis.
Overall survival (OS) was defined by the time elapsing
from the date of diagnosis to either the date of death or
the date of the last contact. Disease-free survival (DFS)
was calculated from the date of surgery to the date of the
first documented clinical disease recurrence. Cases with
surgical mortality, defined as death within one month of
surgery, and patients who received only operative biopsy
for tissue proof were excluded from the survival analyses.
Kaplan-Meier analysis was used to determine the OS and
DFS.21 The log-rank test was applied to compare survival
outcomes between or among groups. Statistical signifi-
cance was defined as p < 0.05.
Results
Demographic data
A total of 2,034 patients with histologically proven HCC
were enrolled. Among them, 1,594 (78.33%) were males
and 441 (21.67%) were females. The mean age was 55 years
(4–88 years). HBV infection was detected in 1,215 (63.41%)
patients, and anti-HCV was detected in 533 (28.05%)
patients. A total of 585 (49.65%) patients had T1 disease,
223 (12.91%) had T2 disease, 392 (22.69%) had T3 disease,
and 255 (14.76%) had T4 disease according to the sixth
edition of the AJCC TNM staging system for HCC.17
Intra-operative lymphadenectomy or lymph node biopsy
was performed in 170 (8.36%) patients because of a suspi-
cious enlarged lymph node, but only 25 (1.23%) patients
had pathologically proven LNM (N1 disease). A total of
50 (4.19%) patients developed distant metastases (M1 dis-
ease) until the endpoint of this study. Of 25 patients with
LNM, three underwent only open biopsy for a postopera-
tive histological diagnosis. Of the 195 lymph nodes dis-
sected from these 25 N1 patients, 77 were neoplastic
(mean, 3.08; range, 1–8). The number of metastatic lymph
nodes was not related to patient survival (p = 0.13).
Clinicopathologic characteristics with respect to LNM
The relationship between clinical characteristics and LNM
in HCC is summarised in Table 1. Age, gender, cigarette
smoking, and alcohol consumption were not significantly
associated with LNM. In terms of viral infection, neither
HBV infection nor HCV infection were related to develop-
ment of LNM (1.23% vs. 1.28%, p = 0.587, with vs. without
HBV infection, respectively; and 0.75% vs. 1.44%, p = 0.265,
with vs. without HCV infection, respectively). Preoperative
albumin, bilirubin, alpha-foetoprotein levels, and tumour
T stage were not significantly associated with LNM.
However, patients with high preoperative CEA levels (> 10
ng/mL; normal is ≤ 5 ng/mL in our hospital) had a higher
incidence of LNM than did those with low preoperative
CEA levels (≤ 10 ng/mL) (15.38% vs. 3.79%, p = 0.042). The
result was still statistically significant when the mixed
tumours (combined HCC and cholangiocarcinoma) were
excluded from the analysis (15.38% vs. 3.48%, p = 0.031).
Furthermore, M1 disease was significantly associated
with LNM compared with M0 disease (8.00% vs. 0.96%,
p < 0.001).
Tumour size of greater than 5 cm, encapsulated HCC,
tumours with microvascular invasion, cancerous thrombi,
and worse histological grade were associated with a
higher incidence of LNM. HCC with LNM was larger in
size (mean diameter, 9.44 cm) compared with HCC with-
out LNM (5.85 cm; p = 0.016). Nevertheless, effects of
tumour rupture and daughter nodules in LNM did not
reach statistical significance (p = 0.631 and 0.857, respec-
tively) (Table 2).
Patient survival with respect to LNM
The overall median DFS was 15.9 months (95% CI, 13.6–
18.2 months) in this study. The 2-year DFS rate was 0% 
in N1 disease and 34.1% in N0 disease (p = 0.001). The
median DFS was 5.8 months (95% CI, 4.0–7.6 months) in
HCC with LNM and 16.3 months (95% CI, 13.9–18.2
months) in HCC without LNM (p = 0.001). The DFS of
HCC with and without LNM is illustrated in Figure 1.
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Table 1. Relationship between clinical characteristics and lymph node metastasis (LNM) in hepatocellular carcinoma (HCC)
Without LNM With LNM (%) p
Age (yr)
≤ 60 1,149 16 (1.37) 0.514
> 60 849 9 (1.05)
Sex
Male 1,568 21 (1.32) 0.490
Female 435 4 (0.91)
Cigarette smoking
Yes 776 15 (1.90) 0.208
No 1,038 10 (0.95)
Alcohol
Yes 563 9 (1.57) 0.496
No 1,038 10 (0.95)
HBV
Positive 1,200 15 (1.23) 0.587
Negative 540 7 (1.28)
Unknown 151 3 (1.95)
HCV
Positive 529 4 (0.75) 0.265
Negative 888 13 (1.44)
Unknown 458 8 (1.72)
Preoperative AFP (ng/mL)
> 400 1,213 15 (1.22) 0.934
≤ 400 588 7 (1.18)
Preoperative CEA (ng/mL)
Including mixed tumour*
≤ 10 305 12 (3.79) 0.042
> 10 11 2 (15.38)
Excluding mixed tumour
> 10 305 11 (3.48) 0.031
≤ 10 11 2 (15.38)
Albumin (g/dL)
≤ 2.8 67 1 (1.47) 0.776
> 2.8 1,617 18 (1.10)
Total bilirubin (mg/dL)
≤ 2 1,718 20 (1.15) 0.708
> 2 130 2 (1.52)
T stage
T1 853 5 (0.58) 0.072
T2 220 3 (1.35)
T3 488 4 (0.81)
T4 248 7 (2.75)
M stage
M0 1,131 11 (0.96) < 0.01
M1 46 4 (8.00)
*Combined HCC and intra-hepatic cholangiocarcinoma. HBV = hepatitis B virus; HCV = hepatitis C virus; CEA = carcinoembryonic antigen.
The median OS was 50.93 months (95% CI, 43.5–58.3
months) in this study. The 1-year, 3-year, and 5-year OS
rates for N0 disease were 72.6%, 54.9%, and 38.4%, respec-
tively. The 1-year, 3-year, and 5-year OS rates for N1 dis-
ease were 36.4%, 13.6%, and 13.6%, respectively. Five N1
patients survived for more than 2 years after the opera-
tion. The median OS was 11.0 months (95% CI, 8.4–13.6
months) in HCC with LNM and 52.3 months (95% CI,
44.6–60.0 months) in HCC without LNM (p < 0.001). Of
patients with LNM, radical operation and lymphadenec-
tomy resulted in significantly longer OS (median OS, 11.3
months; 95% CI, 5.4–17.3 months) compared with only
open biopsy for tissue proof (median OS, 0.95 months;
95% CI, 0.64–1.3 months) (p = 0.012). The three patients
who underwent only open biopsy for a postoperative his-
tological diagnosis died of complications of metastatic
portal vein thrombi and liver failure. The OS of HCC with
and without LNM is depicted in Figure 2. The DFS and
OS outcomes are summarised in Table 3.
Figure 3 shows the OS curve of 66 randomised N0
patients and 22 N1 patients. The selected N0 patients
were matched with N1 patients for age, gender, viral sta-
tus, T stage, M stage, and resection margins. All of these
patients underwent radical operations for their primary
HCC. Three N1 patients who underwent only open biopsy
for a histological diagnosis were excluded from this analy-
sis. Two of these three patients succumbed to surgical
mortality. HCC with LNM was still significantly associ-
ated with worse OS than HCC without LNM when the
other variables were matched (p = 0.001).
A total of 13 of 22 N1 HCC patients who underwent
surgery developed recurrence. The recurrence rate was 59%.
The most common site of recurrence was intra-hepatic (9
patients, 69.2%), followed by peritoneal (3 patients, 23.1%)
and retroperitoneal (1 patient, 7.7%). The mean overall
survival of the nine patients without recurrence was 
6.02 months, with the longest reaching 15.5 months.
Among them, one patient died of inadvertent choking
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Table 2. Relationship between pathological features and lymph node metastasis (LNM) in hepatocellular carcinoma (HCC)
Without LNM With LNM (%) p
Tumour size (cm)
≤ 5 981 6 (0.61) 0.011
> 5 899 17 (1.90)
Mean tumour size (cm) 5.85 9.44 0.016
Encapsulation
Yes 1,182 5 (0.42) < 0.001
No 497 14 (2.73)
Tumour rupture
Yes 214 1 (0.47) 0.631
No 1,665 20 (1.19)
Microvascular invasion
Yes 454 13 (2.78) 0.002
No 1,253 5 (0.40)
Cancerous thrombi
Yes 516 14 (2.64) 0.003
No 1,460 5 (0.34)
Daughter nodules
Yes 374 2 (0.54) 0.857
No 1,303 11 (0.83)
Edmonson and Steiner grade
I 78 1 (5.32) < 0.001
II 920 2 (10.53)
III 760 4 (21.15)
IV 162 12 (63.15)
and respiratory failure 2 months after surgery, two died
of liver failure and ascites more than 2 months after 
surgery, and another patient died of gastric ulcer bleeding
1.5 months after surgery. The remaining three patients
did not develop recurrences until the endpoint of this
study, and the last two patients did not come to our clinic
for follow-up after stabilisation of their disease.
Discussion
The incidence of LNM in operable HCC is very low.
Changchien et al22 in a hospital-based retrospective analy-
sis in 2008, reported that 1.5% of 6,381 HCC patients
developed LNM. However, 2,890 (42.3%) patients in the
study were not treated, and fewer than 10% of patients
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Figure 1. Disease-free survival (DFS) of hepatocellular carcinoma
(HCC) with and without lymph node metastasis (LNM). The solid
line represents N0 patients, and the dashed line represents N1
patients. The horizontal axis is the survival in years, and the ver-
tical axis is the percentile cumulative survival. The median DFS was
5.8 months (95% CI, 4.0–7.6 months) for HCC with LNM and
16.3 months (95% CI, 13.9–18.2 months) for HCC without LNM
(p = 0.001). HCC with LNM had a significantly poorer DFS.
HCC = hepatocellular carcinoma; LNM = lymph node metastasis.
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Figure 2. Overall survival (OS) of hepatocellular carcinoma
(HCC) with and without lymph node metastasis (LNM). The
solid line represents N0 patients, and the dashed line represents
N1 patients. The horizontal axis is the survival in years, and the
vertical axis is the percentile cumulative survival. The median OS
was 11.0 months (95% CI, 8.4–13.6 months) for HCC with LNM
and 52.3 months (95% CI, 44.6–60.0 months) for HCC without
LNM (p < 0.001). HCC with LNM had a significantly poorer OS.
HCC = hepatocellular carcinoma; LNM = lymph node metastasis.
Table 3. Survival outcomes with respect to lymph node metastasis (LNM) in hepatocellular carcinoma (HCC)
Mean (95% CI) Median (95% CI) p
Disease-free Survival (mo)
Without LNM 54.2 (46.8–61.6) 16.3 (13.9–18.2) 0.001
With LNM 7.2 (4.9–9.4) 5.8 (4.0–7.6)
Operation 7.6 (5.3–9.8) 6.7 (4.9–8.6) 0.013
Biopsy only 1.7 (1.7–1.7) 1.71 (–)
Overall 53.8 (46.5–61.2) 15.9 (13.6–18.2)
Overall survival (mo)
Without LNM 54.2 (46.8–61.6) 52.3 (44.6–60.0) < 0.001
With LNM 29.7 (11.6–47.7) 11.0 (8.4–13.6)
Operation 32.5 (12.6–52.3) 11.3 (5.4–17.3) 0.012
Biopsy only 3.9 (0.0–9.9) 0.95 (0.64–1.3)
Overall 118.9 (108.9–128.7) 50.93 (43.5–58.3)
underwent surgery. Thus, the results may not be appro-
priately applied to the operable HCC patients. In a 2007
study evaluating the value of routine complete lympha-
denectomy, Sun et al23 indicated that the incidence of
LNM was 5.1% (49/968). According to the study performed
by the Liver Cancer Study Group of Japan24 in 1990, 417 of
1,374 patients had LNM (30.3%) in the autopsy series. The
incidence was 1.7% to 2.2% in resectable cases. Grobmyer
et al25 sampled perihepatic lymph nodes in 100 patients
undergoing resection for primary and metastatic hepatic
malignancy. Eleven patients had HCC and none devel-
oped LNM (0%). In 2002, Vauthey et al2 proposed a sim-
plified staging system for HCC and reported that, in their
series, the incidence of LNM was 3.2% (18/557). In a pros-
pective study, Ercolani et al26 performed routine lym-
phadenectomy in 120 patients undergoing liver resections
for hepatic malignancies and reported that 7.5% of opera-
ble HCC patients had LNM. Being the second largest
study in terms of patient number, our study showed that
the incidence of LNM was 1.23% (25/2,034). This result is
compatible with those of the other reports, confirming
the rarity of LNM in operable HCC patients. The inci-
dence and respective findings of HCC with LNM in the
literature are summarised in Table 4.2,22–26,30
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Figure 3. Survival outcomes matched for clinicopathological
variables. The solid line represents N0 patients, and the dashed
line represents N1 patients. The horizontal axis is the survival in
years, and the vertical axis is the percentile cumulative survival. 
A total of 66 randomly selected N0 patients matched for age,
sex, viral status, T stage, and resection margin with 22 N1
patients were analysed. Three N1 patients who underwent only
biopsy for tissue proof were excluded. HCC with LNM still had 
a significantly poorer OS than HCC without LNM when these
variables were matched (p = 0.001). HCC = hepatocellular carci-
noma; LNM = lymph node metastasis.
Table 4. Incidence and clinical pictures of HCC with LNM in the literature2,22–26,30
Author, yr
No. of No. of Incidence 
Special remarks
LNM patients (%)
Shen, 201030 39 523 7.45 Risk factors for LNM included multiple nodules,
cancerous thrombi, noncirrhotic liver, and 
nonhepatitis status
Changchien, 200822 94 6,381 1.5 ≤ 10% of total patients underwent surgery
Sun, 200723 49 968 5.1 Risk factors for LNM included CA-199, satellite lesions,
large tumour (> 5 cm), cancerous thrombi, no 
HBV/HCV infection, and absence of liver cirrhosis
Grobmyer, 200625 0 11 0 Low yield when no evidence of LNM on pre-operative 
CT or PET scans or at the time of exploration
Ercolani, 200426 3 40 7.5 Risk factors for LNM included multiple nodules
Vauthey, 20022 18 557 3.2 Survival of lymph node involvement matched that of 
patients with major vascular invasion
Liver Cancer Study Group 417 1,374 30.3 The incidence in resectable cases was 1.7−2.2%, 
of Japan, 199024 autopsy series
Present study 25 2,034 1.23 Risk factors included tumour size, cancerous thrombi,
tumour grading, tumour staging, and infiltrative
growth pattern
CEA may be helpful in predicting LNM
HCC = hepatocellular carcinoma; LNM = lymph node metastasis; HBV = hepatitis B virus; HCV = hepatitis C virus; CT = computed tomography;
PET = positron emission tomography; CEA = carcinoembryonic antigen.
One might question the reliability of our intra-operative
lymph node examination and indication for lymphade-
nectomy. In a retrospective review related to peri-hepatic
lymph nodes, Kokudo et al27 concluded that, “all positive
nodes were macroscopically enlarged to a certain degree
and palpated as firm by the surgeon.” A very low rate of
pathologically positive nodes among clinically unsuspi-
cious nodes (1%) was also reported in a previous study.
The incidence of definite occult metastatic disease was
concluded to be very low, and routine intra-operative
sampling of peri-hepatic lymph nodes without evidence
of disease involvement on preoperative images or intra-
operative explorations had a low yield.25 This conclusion
was echoed by another report which found a low incidence
of missed LNM diagnosis and few benefits of routine
complete lymphadenectomy.23 In our experience, routine
peri-hepatic lymph node dissection carried a higher risk
of postoperative complications including ascites for-
mation and may hamper further treatment such as liver
transplantation. Our suggestion, therefore, was that intra-
operative lymph node exploration (careful palpation and
examination of the hepatic hilum and hepatoduodenal
ligament), as opposed to routine lymph node dissection,
should be adopted. Lymphadenectomy (skeletonisation)
should be performed to remove lymph nodes with con-
nective tissue in the hilar area, hepatoduodenal ligament,
and common hepatic artery stations when suspicious
enlarged lymph nodes are found intra-operatively.
Our study showed that a high preoperative CEA level
(> 10 ng/mL) was significantly associated with the occur-
rence of LNM. This result was still statistically significant
when mixed tumours (combined HCC and cholangiocar-
cinoma) were excluded from the analysis. Although lack-
ing statistical significance, a recent study reported that
patients with positive preoperative CA-199 (> 37 U/L) had
a higher incidence of LNM (3.1% vs. 1.7%, p = 0.412).23
However, their study did not investigate the relationship
between CEA level and LNM. This relationship was men-
tioned in another report that showed that higher CEA
expression can be found in patients with LNM and recur-
rent tumours of the fibrolamellar variant of HCC. They
thus concluded that CEA expression might be associ-
ated with the aggressive biological characteristics of this
tumour.14 However, this conclusion was based on a case
report study. In this study, a high preoperative CEA level
of > 10 ng/mL is a risk factor for LNM in HCC, and HCC
with LNM may be a special type that has the potential for
dual differentiation into both HCC and intra-hepatic
cholangiocarcinoma. Further studies, including immu-
nohistochemical studies, are warranted to validate this
hypothesis.
In addition to preoperative CEA level, a significantly
higher incidence of LNM was associated with larger
tumour size (> 5 cm), presence of microvascular invasion,
and tumours with a worse histological grade. These find-
ings were consistent with those of a recent report that
showed that large tumours, cancerous thrombi, and satel-
lite nodules were associated with LNM.23 Furthermore,
our study showed that HCC with LNM was usually nonen-
capsulated. HCC was first proposed to be classified into
encapsulated and nonencapsulated in 1977. The authors
suggested that encapsulated HCC was usually well differ-
entiated with less frequent intravenous tumour invasion.
They tended to have a slowly expanding growth pattern
which rendered a longer survival.28 Conversely, nonen-
capsulated HCC may have a more malignant behaviour.
Therefore, HCC with LNM tends to be the infiltrating
type that has a rapid growth pattern and invasive clinical
behaviour. Altogether, our findings suggest that HCC
with LNM may be a sign of advanced tumour stage, and
more aggressive surgical treatment and more frequent
postoperative follow-up should thus be applied whenever
LNM is suspected or confirmed.
Our analyses show that HCC with LNM had a much
worse DFS and OS than did HCC without LNM. After
matching patients with and without LNM, OS was still
significantly worse in patients with LNM. In other words,
LNM was a poor prognostic factor for HCC. This corre-
sponds with the proposal of Vauthey JN and the latest
edition of AJCC on the TNM staging system of HCC in
that LNM represents a more advanced stage. According
to the Barcelona Clinic Liver Cancer staging classifica-
tion,29 HCC with LNM, which represents an advanced
stage or stage C disease, should receive palliative treat-
ments or new agents in the setting of phase II investiga-
tions or randomised controlled trials. In other words,
radical resection is not suggested for HCC with LNM.
However, our study found that hepatic resection and lym-
phadenectomy was associated with a better OS than only
surgical biopsy for tissue proof. Although the OS of N1
disease was still significantly inferior to that of N0 disease
after radical surgery, there were still five patients who sur-
vived for more than 2 years after surgery. In other words,
aggressive surgical treatment is still suggested even when
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LNM is noted pre- or intra-operatively. LNM was not a
contraindication for curative surgery for HCC. Our result
was comparable with that of the series reported by Shen
et al30 who concluded that LNM has a poor prognostic
impact on HCC. The better outcome reported in that study
was probably due to their routine performance of regional
lymphadenectomy. Nevertheless, as discussed previously,
our experience suggests that peri-hepatic lymph node 
dissection should only be performed when lymph node
involvement is suspected pre- or intra-operatively.
This study had some limitations. First, because this
study was a retrospective hospital-based analysis, incom-
plete data were inevitable when reviewing records from a
very long time ago. Second, because the preoperative CEA
level was not routinely obtained, the resulting statistical
value may not be persuasive enough. Third, inconsistent
surgery may be related to performance by different hepa-
tobiliary surgeons. Therefore, a well-designed cohort study
with long-term follow-up is required to further validate
the results of our study.
In conclusion, this large-scale comprehensive analysis
identified a low incidence of LNM in HCC and a very poor
prognosis of HCC when LNM occurred. A high preopera-
tive CEA level (> 10 ng/mL) is a significant risk factor for
LNM in HCC. Patients should have their preoperative
CEA level determined to evaluate the risk of LNM. HCC
with LNM tends to be the infiltrating type with a larger
tumour size (> 5 cm), presence of microvascular invasion,
and poorer histological grade. Furthermore, liver resection
with lymphadenectomy is possibly beneficial to patients
with HCC accompanied by LNM. Therefore, LNM may
not be a contraindication for curative resection for HCC,
and more aggressive surgical treatment, including lymph
node dissection, is suggested when LNM is suspected.
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